Hiltonol

Summary

Hiltonol (poly-ICLC) is a synthetic double‑stranded RNA that functions as a Toll‑like receptor 3 (TLR3) agonist. It is being investigated as an immunostimulatory adjuvant for vaccines and as a monotherapy or component of combination regimens in cancer, including glioblastoma, prostate cancer and other solid tumours. The compound is currently classified as investigational and is administered by injection (intramuscular, intratumoral, subcutaneous or intranasal).

Mechanism of Action

Poly‑ICLC mimics viral double‑stranded RNA and binds to TLR3 located in endosomal membranes of dendritic cells, macrophages and other innate immune cells. Activation of TLR3 triggers the TRIF signaling pathway, leading to robust production of type I interferons (IFN‑α/β) and pro‑inflammatory cytokines such as IL‑12 and IL‑1β. These signals promote dendritic‑cell maturation, enhance antigen presentation, and stimulate NK‑cell and T‑cell responses, thereby amplifying adaptive immunity against co‑administered antigens or tumour cells.

What the Research Shows

Pre‑clinical work demonstrates that poly‑ICLC can induce antiviral‑like innate responses and directly kill glioblastoma cells, while enhancing the efficacy of vaccines and checkpoint inhibitors in murine models. Early‑phase clinical investigations have explored Hiltonol as a vaccine adjuvant and as an intratumoral immunotherapy. A pilot phase‑I study combining intratumoral Hiltonol with dendritic‑cell vaccination and radiotherapy reported safety, increased IFN‑α/β transcripts in peripheral blood, and stable disease in nine of fifteen patients. A systematic review of glioblastoma studies concluded that poly‑ICLC is safe and capable of eliciting immune activation when paired with vaccines. A recent phase‑I prostate‑cancer trial using intratumoral and intramuscular injections found no dose‑limiting toxicities, demonstrated immune cell infiltration, and suggested biochemical improvements, though objective tumour regressions were not reported. Collectively, the data indicate immunologic activity and tolerability, but efficacy remains to be confirmed in larger trials.

Reported Benefits

Evidence from early trials suggests Hiltonol can safely activate innate immunity, increase type‑I interferon and cytokine production, and improve dendritic‑cell maturation. When used with vaccines or radiotherapy, it has been associated with stable disease and enhanced immune cell infiltration in tumours, indicating potential to convert immunologically 'cold' cancers into responsive ones. Its adjuvant properties may also boost antigen‑specific responses in vaccine platforms.

Limitations of the Evidence

The clinical data are limited to small, non‑randomised phase‑I studies with modest patient numbers. No objective tumour regressions have been demonstrated, and long‑term survival benefits are unknown. Efficacy signals are preliminary, and the optimal dosing schedule, route, and combination partners remain to be defined. Hiltonol is not yet approved for any indication, and regulatory status reflects its investigational nature.

Safety Considerations

Across the cited studies, Hiltonol was well tolerated with no dose‑limiting toxicities. Reported adverse events were typical of cytokine activation, such as transient flu‑like symptoms, fever, and mild injection‑site reactions. No serious adverse events were attributed to the drug in the prostate‑cancer or combination immunotherapy trials. Ongoing monitoring for systemic inflammation remains prudent when using potent TLR3 agonists.

How It Is Administered

Hiltonol is formulated as a complexed double‑stranded RNA and can be delivered by injection. Reported routes include intramuscular, intratumoral, subcutaneous and intranasal administration. Dosing regimens in published trials vary, ranging from single‑dose intratumoral injections to daily intradermal administrations as part of combination protocols. Formulation is supplied as a sterile injectable solution.

Routes of Administration

Goals & Uses

• Antitumor activityOncologyLow
• Neuroprotection/neuroimmune modulationNeurologyLow
• Innate immune activationImmunostimulationHigh
• Infectious disease vaccine adjuvantVaccinologyModerate
• Cancer vaccine adjuvantImmunotherapyModerate

Contraindications

• Known hypersensitivity to poly-ICLC componentsAllergicHigh
• Active severe systemic infectionInfectiousModerate
• Severe autoimmune diseaseImmunologicalHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalCommon
• Cytokine release syndromeImmunologicRareSystemic inflammatory response from immune activation
• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• FatigueGeneralCommonLow energy or tiredness
• Elevated liver enzymes (transaminases)HepaticUncommon

Drug Interactions

• Anticoagulants (e.g., warfarin)Low
• Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
• Other TLR agonists / immunostimulantsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patients (>75 years)AgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with severe hepatic impairmentHepaticRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; available only in clinical trial settings.
• United StatesInvestigationalUsed exclusively under IND applications; not FDA-approved. Orphan Drug Designation obtained for certain indications.
• United KingdomInvestigationalNo MHRA approval; investigational use only.

Not FDA-approved; used under IND applications in clinical trials. Designated as an investigational product by Oncovir, Inc. Has received Orphan Drug Designation for certain oncology indications. Available to qualified researchers under IND.

Evidence & Sources

• Vaccine adjuvant uses of poly-IC and derivatives
  Journal ArticleModerateMartins KA, Bavari S, Salazar AM2015-01-01T00:00:00.000000Z
• Trial Watch: Toll-like receptor agonists for cancer therapy
  Journal ArticleModerateVacchelli E, et al.2013-01-01T00:00:00.000000Z
• Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
  Journal ArticleModerateRodríguez-Ruiz ME, et al.2018-01-01T00:00:00.000000Z
• A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
  Journal ArticleHighDe Waele J, et al.2021-01-01T00:00:00.000000Z
• Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Modulating the cold tumor microenvironment
  Journal ArticleModerateNair SS, et al.2025-01-01T00:00:00.000000Z
• Trial Watch: Toll-like receptor agonists in cancer immunotherapy
  Journal ArticleModerateSmith M, et al.2018-01-01T00:00:00.000000Z

Frequently Asked Questions